BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 15537754)

  • 1. Calcium(II) selectively induces alpha-synuclein annular oligomers via interaction with the C-terminal domain.
    Lowe R; Pountney DL; Jensen PH; Gai WP; Voelcker NH
    Protein Sci; 2004 Dec; 13(12):3245-52. PubMed ID: 15537754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Copper- and iron-induced differential fibril formation in alpha-synuclein: TEM study.
    Bharathi ; Indi SS; Rao KS
    Neurosci Lett; 2007 Sep; 424(2):78-82. PubMed ID: 17714865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments.
    Emadi S; Liu R; Yuan B; Schulz P; McAllister C; Lyubchenko Y; Messer A; Sierks MR
    Biochemistry; 2004 Mar; 43(10):2871-8. PubMed ID: 15005622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Forcing nonamyloidogenic beta-synuclein to fibrillate.
    Yamin G; Munishkina LA; Karymov MA; Lyubchenko YL; Uversky VN; Fink AL
    Biochemistry; 2005 Jun; 44(25):9096-107. PubMed ID: 15966733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid self-assembly of alpha-synuclein observed by in situ atomic force microscopy.
    Hoyer W; Cherny D; Subramaniam V; Jovin TM
    J Mol Biol; 2004 Jun; 340(1):127-39. PubMed ID: 15184027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro.
    Hoyer W; Cherny D; Subramaniam V; Jovin TM
    Biochemistry; 2004 Dec; 43(51):16233-42. PubMed ID: 15610017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural evidence for alpha-synuclein fibrils using in situ atomic force microscopy.
    Zhang F; Ji LN; Tang L; Hu J; Hu HY; Xu HJ; He JH
    Acta Biochim Biophys Sin (Shanghai); 2005 Feb; 37(2):113-8. PubMed ID: 15685368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Annular alpha-synuclein oligomers are potentially toxic agents in alpha-synucleinopathy. Hypothesis.
    Pountney DL; Voelcker NH; Gai WP
    Neurotox Res; 2005; 7(1-2):59-67. PubMed ID: 15639798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Copper(II)-induced self-oligomerization of alpha-synuclein.
    Paik SR; Shin HJ; Lee JH; Chang CS; Kim J
    Biochem J; 1999 Jun; 340 ( Pt 3)(Pt 3):821-8. PubMed ID: 10359669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metal-catalyzed oxidation of alpha-synuclein in the presence of Copper(II) and hydrogen peroxide.
    Paik SR; Shin HJ; Lee JH
    Arch Biochem Biophys; 2000 Jun; 378(2):269-77. PubMed ID: 10860544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A peptide motif consisting of glycine, alanine, and valine is required for the fibrillization and cytotoxicity of human alpha-synuclein.
    Du HN; Tang L; Luo XY; Li HT; Hu J; Zhou JW; Hu HY
    Biochemistry; 2003 Jul; 42(29):8870-8. PubMed ID: 12873148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of alpha-synuclein carboxy-terminus on fibril formation in vitro.
    Murray IV; Giasson BI; Quinn SM; Koppaka V; Axelsen PH; Ischiropoulos H; Trojanowski JQ; Lee VM
    Biochemistry; 2003 Jul; 42(28):8530-40. PubMed ID: 12859200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of nitration on the structure and aggregation of alpha-synuclein.
    Uversky VN; Yamin G; Munishkina LA; Karymov MA; Millett IS; Doniach S; Lyubchenko YL; Fink AL
    Brain Res Mol Brain Res; 2005 Mar; 134(1):84-102. PubMed ID: 15790533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders.
    El-Agnaf OM; Paleologou KE; Greer B; Abogrein AM; King JE; Salem SA; Fullwood NJ; Benson FE; Hewitt R; Ford KJ; Martin FL; Harriott P; Cookson MR; Allsop D
    FASEB J; 2004 Aug; 18(11):1315-7. PubMed ID: 15180968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of metals on herbicides-alpha-synuclein association: a possible factor in neurodegenerative disease studied by capillary electrophoresis.
    André C; Truong TT; Robert JF; Guillaume YC
    Electrophoresis; 2005 Sep; 26(17):3256-64. PubMed ID: 16143978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural transformation and aggregation of human alpha-synuclein in trifluoroethanol: non-amyloid component sequence is essential and beta-sheet formation is prerequisite to aggregation.
    Li HT; Du HN; Tang L; Hu J; Hu HY
    Biopolymers; 2002 Aug; 64(4):221-6. PubMed ID: 12115139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Annular alpha-synuclein species from purified multiple system atrophy inclusions.
    Pountney DL; Lowe R; Quilty M; Vickers JC; Voelcker NH; Gai WP
    J Neurochem; 2004 Jul; 90(2):502-12. PubMed ID: 15228606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils.
    Lashuel HA; Petre BM; Wall J; Simon M; Nowak RJ; Walz T; Lansbury PT
    J Mol Biol; 2002 Oct; 322(5):1089-102. PubMed ID: 12367530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dependence of alpha-synuclein aggregate morphology on solution conditions.
    Hoyer W; Antony T; Cherny D; Heim G; Jovin TM; Subramaniam V
    J Mol Biol; 2002 Sep; 322(2):383-93. PubMed ID: 12217698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.
    Conway KA; Harper JD; Lansbury PT
    Nat Med; 1998 Nov; 4(11):1318-20. PubMed ID: 9809558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.